Allergan
Two products with nothing in common except a habit of publishing the inconvenient part — the largest, least ambiguous cosmetic result in this register alongside two harms that do not reverse, and the only acne label anywhere here that reports the drug working differently in women than in men.
MODEL
New Drug Application, manufactured product, retail pharmacy dispensing on a prescriber's script.
The brand verdict
Two products assessed, and they have almost nothing to do with each other clinically. What they share is a willingness to print the thing that complicates the sale: Latisse's postmarketing section names the periorbital fat atrophy that hollows an eyelid, and Aczone's clinical studies section reports that female subjects responded better than male ones — a sex difference in effect, published on a label, which nothing else in this register does.
Latisse is bimatoprost 0.03%, the approved original that the generic and compounded lash serums elsewhere in this register are copies of, and its efficacy is not in question: 78% of subjects improved by at least one Global Eyelash Assessment grade at sixteen weeks against 18% on vehicle, with lash length up 1.4 mm against 0.1 mm.
The disclosure is close to exemplary. Eight separate warning sections. Results published at six timepoints rather than only at the endpoint. Digital image analysis of length, thickness and darkness reported separately from the investigator scale. Both fill volumes published with their applicator counts, so the supply claim can be checked against the manufacturer's own component count — which is the only place in this register that is true.
What makes it conditional is an asymmetry rather than a doubt. The label states that lashes return to pre-treatment level on stopping, that increased brown iris pigmentation is likely to be permanent, and — in postmarketing — that periorbital fat atrophy can deepen the eyelid sulcus and cause ptosis. The benefit is temporary and two of the harms are not. That is a legitimate trade for someone who has read it and a poor one for someone who has not.
The commercial context is the reason this review matters beyond the drug. Brand Latisse averages around $214 for 5 ml; generic bimatoprost starts near $61. The telehealth service at R-32 sells that generic at $175 a bottle and mentions neither the iris nor the eyelid. Everything a buyer needs is on this label, and almost none of it travels with the molecule.
- The largest, least ambiguous efficacy result in this register: 78% against 18%.
- Results published at weeks 1, 4, 8, 12, 16 and 20.
- Digital image analysis of length, thickness and darkness reported separately.
- Both fill volumes published with applicator counts, so cost per night is exact.
- States explicitly that more product will not grow more lashes.
- States explicitly that the effect reverses on discontinuation.
- Instructs single use of each sterile applicator and explains the bacterial keratitis risk.
- Names periorbital fat atrophy, deepened sulcus, ptosis, madarosis and trichorrhexis.
- Warns that iris pigmentation is likely to be permanent and describes how it spreads.
- Declares benzalkonium chloride and its effect on soft contact lenses.
- Flags the interaction with prostaglandin analogues used for intraocular pressure.
The range
- R-462026-08-02
Latisse
BIMATOPROST OPHTHALMIC SOLUTION 0.03%It works, unambiguously — 78% of users versus 18% on vehicle at sixteen weeks. It can also permanently darken your iris and hollow the fat pad behind your upper eyelid. Both facts are on the same label, which is exactly why this review exists.
CONDITIONAL$214 PER 5 ML BOTTLE
- R-552026-08-03
Aczone
DAPSONE GEL 5%The one acne label in this register that publishes a sex difference — women responded better than men, and it says so. The local reactions are indistinguishable from the vehicle. The effect is the smallest here, and the price depends entirely on whether you ask for the generic.
CONDITIONAL$56 PER TUBE
What repeats across the range
These are the findings a single review cannot make. Each one appears in more than one product, and each is drawn from the reviews above rather than from an impression of the brand.
- 01
The supply arithmetic actually works
3 ml with 70 applicators, 5 ml with 140, one applicator per eye per night. That is 70 nights from the 5 ml bottle, stated by the manufacturer in the same paragraph as the fill volume. No other product in this register lets a buyer verify a supply claim from the manufacturer's own component count.
- 02
Permanent harms, reversible benefit
Iris pigmentation is likely to be permanent. Periorbital fat atrophy, deepened eyelid sulcus and ptosis are in postmarketing. Eyelash growth returns to pre-treatment level on discontinuation. A buyer should understand which of those three stops when they do.
- 03
The worst side effect is filed where nobody reads
Prostaglandin-associated periorbitopathy — hollowing above the eye — sits in section 6.2 rather than in the warnings. For a product bought largely by people trying to look less tired, it is the single most decision-relevant fact on the label, and it is in the section written for pharmacovigilance rather than for patients.
- 04
The only acne label here that reports a sex difference
Aczone's clinical studies section states that female subjects tended to have greater lesion reductions and greater success than males. Every other label in this register publishes who was enrolled; this one publishes that the drug behaved differently in half of them. It is qualitative and carries no numbers, and it is still the most directly applicable sentence on any acne label we have read.
- 05
Population-specific risks are named, not gestured at
Aczone's methemoglobinaemia warning states that G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern and Mediterranean ancestry. Latisse warns that iris pigmentation is likely to be permanent and describes how it spreads. In both cases the risk is attached to the people it falls on rather than left abstract.
- 06
It says the things that reduce sales
Additional applications will not increase growth. Do not apply to the lower lash line. Lashes return to baseline on stopping. Madarosis and eyelash breakage are in postmarketing — lash loss from a lash drug. All four are on the label and none is in any marketing this register has read.
Disclosure scorecard
Not what is in the product — what the company publishes about it, and where. “Findable” means the concentration exists somewhere, such as a help-centre article, rather than on the page you buy from.
SCROLL THE TABLE SIDEWAYS
If you buy one
Latisse
Worth buying for a specific person with a specific problem. Read who.
Aczone
Worth buying for a specific person with a specific problem. Read who.